NASDAQ · CLVRW
Healthcare · Drug Manufacturers - Specialty & Generic
$0.03
Up+$0.00 (+0.00%)
Updated Sep 20, 2026, 10:45 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CLVRW does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning CLVRW.
CLVRW research
Company profile and research snapshot.
CLEVER LEAVES HLDGS WTS
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
GlobeNewswire Inc. · May 11, 2022
BOCA RATON, Fla., May 11, 2022 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, is scheduled to participate in the following investor conferences in May 2022:
GlobeNewswire Inc. · Apr 28, 2022
BOCA RATON, Fla., April 28, 2022 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, will hold a conference call on Thursday, May 12, 2022 at 5:00 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2022. The Company will provide its financial results in a press release prior to the conference call.
GlobeNewswire Inc. · Apr 27, 2022
Clever Leaves Holdings Inc. to expand its capabilities into Europe’s largest medical cannabis market and gain access to around 20,000 pharmacies in Germany through its affiliate Clever Leaves Germany GmbH Clever Leaves Holdings Inc. to expand its capabilities into Europe’s largest medical cannabis market and gain access to around 20,000 pharmacies in Germany through its affiliate Clever Leaves Germany GmbH
GlobeNewswire Inc. · Apr 20, 2022
Under the two-year supply agreement Clever Leaves will deliver CBD Isolate to Biom Therapeutics to manufacture a finished product for clinical trials in the United States Under the two-year supply agreement Clever Leaves will deliver CBD Isolate to Biom Therapeutics to manufacture a finished product for clinical trials in the United States
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CLVRW.
No results
No recent SID articles mention CLVRW.
